Peptide-Based Drugs: A SPOT More Stable

Host defense peptides – in addition to their synthetic analogues, innate defense regulator (IDR) peptides – have recently gained attention as a new strategy for treating challenging infections. These peptides can have a variety of therapeutic functions, such as increasing the recruitment of immune cells to the site of infection and modulating inflammation, as well as targeting biofilms, the bacterial communities…
Read More
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (“BioVaxys”) is pleased to announce that results from its preclinical animal study (also known as the “murine model study”) of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. Previous interim data from the study showed it possessed an excellent emerging tolerability profile…
Read More
A Vancouver company is central to the news Monday morning that Pfizer is close to developing an effective vaccine against the coronavirus. Pfizer said Monday that an early peek at the data on its coronavirus vaccine suggests the shots may be a surprisingly robust 90 per cent effective at preventing COVID-19. Vancouver-based Acuitas Therapeutics, a biotechnology company, is playing a key role through a technology known…
Read More
A new article by NMIN researchers published in the journal Nanoscale sheds light on a potential mechanism by which lipid nanoparticle (LNP) formulations of nucleic acid encapsulate short interfering RNA (siRNA). “Genetic drugs based on RNA or DNA have a remarkable potential to treat virtually any disease,” comments NMIN Scientific Director Dr. Pieter Cullis, who was lead researcher on the study. “By containing…
Read More
AbCellera today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test,…
Read More

The GSC Welcomes Dr. Alexander Wyatt

Dr. Alexander Wyatt, Assistant Professor in the Department of Urological Sciences at UBC and Senior Research Scientist at the Vancouver Prostate Centre, has recently joined the GSC as a Scientist. Dr. Wyatt received his PhD in human genetics from the University of Oxford and conducted his postdoctoral research at the Vancouver Prostate Centre. In 2015, he became a UBC faculty…
Read More

Re-Writing the Code of Life

Two scientists recently shared the Nobel Prize for Chemistry for transforming an obscure bacterial immune mechanism, called CRISPR, into “genetic scissors” – an editing tool for re-writing the code of life. The two female Nobel Prize winners accomplished this through collaboration – which is exactly how two Canadian scientists – also women – are working to crack the code on…
Read More
A Burnaby biotech company has enrolled and dosed its first volunteer with an oral DNA vaccine to prevent COVID-19. On Wednesday, Symvivo Corporation reported that “investigators have enrolled and dosed the first healthy volunteer in its bacTRL-Spike COVID-19 Phase I clinical trial in Australia.” According to the firm, the treatment delivers genetic material to the gut, which directs the body…
Read More
Fresh water is unequivocally one of British Columbia (BC)’s most valuable natural resources and is directly and indirectly tied to the health and wellbeing of British Columbians in immeasurable ways. Monitoring changes in freshwater ecosystems is vital to inform sound decision making by government managers as pressures on this resource intensify. A relatively simple way to measure these changes is…
Read More
Alpha-9 Theranostics Inc.TM, a radiopharmaceutical company developing unique technology for imaging and treatment of metastatic cancer, today announced the completion of a Phase I/II clinical trial of its neuroendocrine tumour imaging agent A9T-1101 at BC Cancer, one of Canada’s premier cancer research and treatment centres. The outcome of the trial confirmed the utility, biodistribution and safety of A9T-1101.  Alpha-9 now…
Read More